Feasibility of a pulmonary rehabilitation programme for patients with symptomatic chronic obstructive pulmonary disease in Georgia: a single-site, randomised controlled trial from the Breathe Well Group.
chronic airways disease
clinical trials
general medicine (see internal medicine)
internal medicine
rehabilitation medicine
thoracic medicine
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
23 09 2022
23 09 2022
Historique:
entrez:
24
9
2022
pubmed:
25
9
2022
medline:
28
9
2022
Statut:
epublish
Résumé
To assess the feasibility of delivering a culturally tailored pulmonary rehabilitation (PR) programme and conducting a definitive randomised controlled trial (RCT). A two-arm, randomised feasibility trial with a mixed-methods process evaluation. Secondary care setting in Georgia, Europe. People with symptomatic spirometry-confirmed chronic obstructive pulmonary disease recruited from primary and secondary care. Participants were randomised in a 1:1 ratio to a control group or intervention comprising 16 twice-weekly group PR sessions tailored to the Georgian setting. Feasibility of the intervention The study recruited 60 participants (as planned): 54 (90%) were male, 10 (17%) had a forced expiratory volume in 1 second of ≤50% predicted. The mean MRC Dyspnoea Score was 3.3 (SD 0.5), and mean St George's Respiratory Questionnaire (SGRQ) 50.9 (SD 17.6). The rehabilitation specialists delivered the PR with fidelity. Thirteen (43.0%) participants attended at least 75% of the 16 planned sessions. Participants and rehabilitation specialists in the qualitative interviews reported that the programme was acceptable, but dropout rates were high in participants who lived outside Tbilisi and had to travel large distances. Outcome data were collected on 63.3% participants at 8 weeks and 88.0% participants at 6 months. Mean change in SGRQ total was -24.9 (95% CI -40.3 to -9.6) at programme end and -4.4 (95% CI -12.3 to 3.4) at 6 months follow-up for the intervention group and -0.5 (95% CI -8.1 to 7.0) and -8.1 (95% CI -16.5 to 0.3) for the usual care group at programme end and 6 months, respectively. It was feasible to deliver the tailored PR intervention. Approaches to improve uptake and adherence warrant further research. ISRCTN16184185.
Identifiants
pubmed: 36153030
pii: bmjopen-2021-056902
doi: 10.1136/bmjopen-2021-056902
pmc: PMC9511586
doi:
Banques de données
ISRCTN
['ISRCTN16184185']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e056902Subventions
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Allergy Asthma Proc. 2015 Jan-Feb;36(1):4-10
pubmed: 25562549
COPD. 2011 Oct;8(5):380-6
pubmed: 21936683
COPD. 2005 Mar;2(1):75-9
pubmed: 17136966
Clin Epidemiol. 2010 Aug 09;2:73-83
pubmed: 20865106
Am Rev Respir Dis. 1992 Jun;145(6):1321-7
pubmed: 1595997
Fam Pract. 2017 Aug 1;34(4):485-490
pubmed: 27694575
Psychol Med. 2020 Nov 03;:1-8
pubmed: 33138872
Thorax. 2020 May;75(5):413-421
pubmed: 32229541
Am J Respir Crit Care Med. 2015 Dec 1;192(11):1373-86
pubmed: 26623686
Thorax. 2013 Sep;68 Suppl 2:ii1-30
pubmed: 23880483
Thorax. 2008 Sep;63(9):775-7
pubmed: 18390634
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
Chest. 2001 Jun;119(6):1705-10
pubmed: 11399694
Curr Opin Pulm Med. 2002 Mar;8(2):81-6
pubmed: 11845001
Lancet Respir Med. 2020 Jun;8(6):585-596
pubmed: 32526187
J Cardiopulm Rehabil Prev. 2019 Sep;39(5):344-349
pubmed: 31348127
Lancet Respir Med. 2014 Mar;2(3):195-203
pubmed: 24621681
Chron Respir Dis. 2019 Jan-Dec;16:1479973119882939
pubmed: 31742441
Chron Respir Dis. 2020 Jan-Dec;17:1479973120952418
pubmed: 32840385
Am Rev Respir Dis. 1990 Apr;141(4 Pt 1):909-13
pubmed: 2327655
Int J Chron Obstruct Pulmon Dis. 2022 Jan 13;17:141-153
pubmed: 35046649
Qual Health Res. 2005 Nov;15(9):1277-88
pubmed: 16204405
Georgian Med News. 2017 Jan;(262):116-120
pubmed: 28252441
Med Sci Sports Exerc. 2003 Aug;35(8):1381-95
pubmed: 12900694
Cochrane Database Syst Rev. 2015 Feb 23;(2):CD003793
pubmed: 25705944
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
J Int Med Res. 2020 Aug;48(8):300060520948382
pubmed: 32840156
Lancet Glob Health. 2018 Dec;6(12):e1363-e1374
pubmed: 30219316
BMC Pulm Med. 2018 Sep 15;18(1):154
pubmed: 30219047
Eur Respir J. 2020 Jun 25;55(6):
pubmed: 32586841
Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
J Eval Clin Pract. 2004 May;10(2):307-12
pubmed: 15189396
Respirology. 2013 Oct;18(7):1089-94
pubmed: 23711304
Int J Chron Obstruct Pulmon Dis. 2015 Aug 28;10:1711-8
pubmed: 26357469
Bull World Health Organ. 2001;79(10):971-9
pubmed: 11693980
Int J Chron Obstruct Pulmon Dis. 2017 Dec 11;12:3533-3539
pubmed: 29270007
Am J Phys Med Rehabil. 2020 Sep;99(9):769-774
pubmed: 32541352
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Chron Respir Dis. 2011;8(2):89-99
pubmed: 21596892
Perspect Clin Res. 2016 Apr-Jun;7(2):100-5
pubmed: 27141477
BMC Pulm Med. 2016 May 10;16(1):70
pubmed: 27160582
NPJ Prim Care Respir Med. 2020 Nov 19;30(1):52
pubmed: 33214560
Eff Clin Pract. 2001 Nov-Dec;4(6):256-62
pubmed: 11769298
Thorax. 2019 Oct;74(10):994-995
pubmed: 31147399
Int J Chron Obstruct Pulmon Dis. 2020 Nov 03;15:2769-2777
pubmed: 33173289
Eur Respir J. 2009 Sep;34(3):648-54
pubmed: 19720809
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941